Korro Bio, Inc.

Korro Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing a new class of genetic medicines based on editing RNA. Its mission is to rewrite the future for patients by repairing the underlying genetic cause of debilitating and life-threatening diseases through innovative RNA therapies. The company's corporate headquarters are located in Cambridge, Massachusetts.

Korro Bio leverages its proprietary Oligonucleotide Promoted Editing of RNA (OPERA®) platform, which harnesses the body's natural RNA editing process to make precise, transient single-base edits. This approach aims to expand the reach of genetic medicines by offering additional precision and tunability. The company is developing a pipeline of programs targeting both rare and highly prevalent diseases, with a focus on the liver and central nervous system. Its lead product candidate, KRRO-121, is being developed for hyperammonemia, including urea cycle disorders and hepatic encephalopathy.

In November 2023, Korro Bio completed a business combination with Frequency Therapeutics, Inc., leading to its shares trading on the Nasdaq Capital Market under the ticker symbol "KRRO." However, the company faced a significant setback in November 2025 when it abandoned its then-lead RNA editing treatment, KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD), due to disappointing study results, which also led to staff reductions and a temporary pause in its collaboration with Novo Nordisk on cardiometabolic diseases. Ram Aiyar serves as the Chief Executive Officer and President, with Loïc Vincent, Ph.D., appointed as Chief Scientific Officer in April 2025. Korro Bio continues to advance its pipeline, with recent activities including presentations at major healthcare conferences in early 2026.